Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M vs $284.068M Est

Benzinga Newsdesk www.benzinga.com Negative 76.2%

Neg 76.2% Neu 0% Pos 0%

Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 million to $275.000 million-$290.000 million vs $284.068 million estimate.